Would a wholistic B cell therapy, such as CAR-T, be more effective in Lupus? We know B cell activation is important but belimumab may work better for short-lived B cells and RTX doesn't deplete most plasma cells. CAR-T, targeting CD19, depletes all B cells. More research is… https://t.co/mPzKIfUC8p https://t.co/cGnI3dggqZ